B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.

@article{Zhang2017BCellLP,
  title={B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.},
  author={Leo Zhang and Krystle J. Nomie and Hui Zhang and Taylor Bell and Lan V. Pham and Sabah Kadri and Jeremy P. Segal and Shaoying Li and Shouhao Zhou and David Almeida dos Santos and Shawana Richard and Shruti Sharma and Wendy Chen and Onyekachukwu Oriabure and Yang Liu and Shengjian Huang and Hui Ling Guo and Zhihong Chen and Wenjing Tao and Carrie J Li and Jack Z. Wang and Bingliang Fang and Jacqueline F Wang and Lei Li and Maria Badillo and Makhdum Ahmed and Selvi Thirumurthi and Steven Y. Huang and Yiping Shao and Laura Lam and Qing Yi and Yitang Wang and Michael Wang},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 15},
  pages={
          4212-4223
        }
}
Purpose: Patients with B-cell lymphomas often relapse after frontline therapy, and novel therapies are urgently needed to provide long-term remission. We established B-cell lymphoma patient-derived xenograft (PDX) models to assess their ability to mimic tumor biology and to identify B-cell lymphoma patient treatment options.Experimental Design: We established the PDX models from 16 patients with diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, or… CONTINUE READING
4
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2015
VIEW 1 EXCERPT